The Pharmacometabodynamics of Gefitinib after Intravenous Administration to Mice: A Preliminary UPLC–IM–MS Study

The effects of intravenous gefitinib (10 mg/kg), an anilinoquinazoline thymidylate kinase inhibitor (TKI), selective for the epidermal growth factor receptor (EGFR), on the urinary metabotypes of mice were studied. We hypothesized that, in response to the administration of gefitinib, there might be...

Descripción completa

Detalles Bibliográficos
Autores principales: Molloy, Billy, Mullin, Lauren, King, Adam, Gethings, Lee A., Plumb, Robert S., Wilson, Ian D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230777/
https://www.ncbi.nlm.nih.gov/pubmed/34208076
http://dx.doi.org/10.3390/metabo11060379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230777/
https://www.ncbi.nlm.nih.gov/pubmed/34208076
http://dx.doi.org/10.3390/metabo11060379

Ejemplares similares